Cargando…

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2 infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–dependent IFN-stimulated genes, in mildly symptomatic COVID-19 patients and show its correlation with serum IFN-α(2) levels, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez, Jonathan, Mommert, Marine, Mouton, William, Pizzorno, Andrés, Brengel-Pesce, Karen, Mezidi, Mehdi, Villard, Marine, Lina, Bruno, Richard, Jean-Christophe, Fassier, Jean-Baptiste, Cheynet, Valérie, Padey, Blandine, Duliere, Victoria, Julien, Thomas, Paul, Stéphane, Bastard, Paul, Belot, Alexandre, Bal, Antonin, Casanova, Jean-Laurent, Rosa-Calatrava, Manuel, Morfin, Florence, Walzer, Thierry, Trouillet-Assant, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352718/ https://www.ncbi.nlm.nih.gov/pubmed/34357402 http://dx.doi.org/10.1084/jem.20211211

Ejemplares similares

Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021)

Type I IFN immunoprofiling in COVID-19 patients
por: Trouillet-Assant, Sophie, et al.
Publicado: (2020)

Type‐I Interferon assessment in 45 minutes using the FilmArray(®) PCR platform in SARS‐CoV‐2 and other viral infections
por: Mommert, Marine, et al.
Publicado: (2021)

Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients
por: Goncalves, David, et al.
Publicado: (2021)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients
por: Pescarmona, Rémi, et al.
Publicado: (2021)

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
por: Vinh, Donald C., et al.
Publicado: (2021)

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
por: Borsani, Oscar, et al.
Publicado: (2021)

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2022)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19
por: Bastard, Paul, et al.
Publicado: (2020)

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
por: Bastard, Paul, et al.
Publicado: (2021)

Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy
por: Pizzorno, Andrés, et al.
Publicado: (2019)

A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022
por: Guibert, Nicolas, et al.
Publicado: (2023)

Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
por: Le Voyer, Tom, et al.
Publicado: (2023)

IFN-γ: A Crucial Player in the Fight Against HBV Infection?
por: Hillaire, Marine Laure Bettina, et al.
Publicado: (2023)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Getting “Inside” Type I IFNs: Type I IFNs in Intracellular Bacterial Infections
por: Snyder, Deann T., et al.
Publicado: (2017)

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia
por: Pizzorno, Andrés, et al.
Publicado: (2020)

A Simple-to-Perform ifn-γ mRNA Gene Expression Assay on Whole Blood Accurately Appraises Varicella Zoster Virus-Specific Cell-Mediated Immunity After Allogeneic Hematopoietic Stem Cell Transplantation
por: Boccard, Mathilde, et al.
Publicado: (2022)

Source of Circulating Pentraxin 3 in Septic Shock Patients
por: Albert Vega, Chloé, et al.
Publicado: (2019)

RIG-I and dsRNA-Induced IFNβ Activation
por: Hausmann, Stéphane, et al.
Publicado: (2008)

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
por: Checkmahomed, Liva, et al.
Publicado: (2020)

Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study
por: Arrestier, Romain, et al.
Publicado: (2022)

Protozoan Parasites and Type I IFNs
por: Silva-Barrios, Sasha, et al.
Publicado: (2017)

Type I IFN is siloed in endosomes
por: Altman, Jennie B., et al.
Publicado: (2020)

Type I IFN Induction via Poly-ICLC Protects Mice against Cryptococcosis
por: Sionov, Edward, et al.
Publicado: (2015)

Auto-antibodies against type I IFNs are associated with severe COVID-19 pneumonia
por: Zhou, Weilin, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022)

Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature
por: Karonitsch, Thomas, et al.
Publicado: (2022)

Role of the IFN I system against the VHSV infection in juvenile Senegalese sole (Solea senegalensis)
por: Alvarez-Torres, Daniel, et al.
Publicado: (2016)

Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus
por: Fillatreau, Simon
Publicado: (2023)

Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del)
por: Bal, A., et al.
Publicado: (2020)

Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome
por: Venet, Fabienne, et al.
Publicado: (2021)

Publisher Correction: Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study
por: Bal, Antonin, et al.
Publicado: (2021)

Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study
por: Bal, Antonin, et al.
Publicado: (2021)

Antiviral Activity of Porcine IFN-λ3 and IFN-α against Porcine Rotavirus In Vitro
por: Deng, Lishuang, et al.
Publicado: (2022)

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
por: Bastard, Paul, et al.
Publicado: (2022)

The Interplay Between Coronavirus and Type I IFN Response
por: Xue, Wenxiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ii9rvokbhvln3b2sf2jdedltal